Search SciPol

Brought to you by
What it does 

S 1078, the FDA Accountability for Public Safety Act, builds upon a provision in the recently-enacted Comprehensive Addiction and Recovery Act of 2016 (Public Law 114-198). In section 106 of that law, a pharmaceutical drug manufacturer submitting a new opioid drug for Food and Drug Administration (FDA) approval would in certain cases first have to submit that application to an FDA advisory committee for their recommendations. S 1078 clarifies that, if the relevant advisory committee recommends against the opioid drug's approval, the FDA Commissioner themself must issue the decision to approve the drug and cannot delegate that decision to other officials within the FDA.

In making this decision, according to S 1078, the FDA Commissioner must also submit a report to the Senate Committee on Health, Education, Labor, and Pensions, and to the House Committee on Energy and Commerce. This report must detail medical and scientific evidence justifying the opioid drug's approval, especially in light of the advisory committee's recommendation to deny approval of the drug, and must disclose any potential conflicts of interest of FDA officials who may have assisted the FDA Commissioner in making the approval decision. Should either Committee request it, the FDA Commissioner must also testify in front of those Committees about the decision to approve the opioid drug.


S 1078 was introduced in the Senate on May 9, 2017, and referred to the Senate Committee on Health, Education, Labor, and Pensions

Creative Commons License This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Please distribute widely but give credit to Duke SciPol and the primary author(s) listed above, linking back to this page if possible.